← 返回

是时候放弃实体瘤的 CAR-T 单药治疗

英文原题:Time to abandon CAR-T monotherapy for solid tumors.

查看英文原题

Time to abandon CAR-T monotherapy for solid tumors.

PubMed 2023/06/05(内容时间) Biochim Biophys Acta Rev Cancer Q1 · IF 11.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

近几十年来,CAR-T(CAR-T)细胞疗法在血液系统恶性肿瘤患者中取得了显著成功。然而,CAR-T 细胞疗法作为单一疗法未能有效治疗实体瘤。通过总结CAR-T 细胞单一疗法治疗实体瘤的挑战,并分析联合策略克服这些障碍的潜在机制,我们发现需要互补性治疗来改善CAR-T 细胞单一疗法在实体瘤中有限且短暂的应答。在CAR-T 联合疗法能够转化为临床应用之前,还需要进一步的数据,尤其是关于疗效、毒性和预测性生物标志物的多中心临床试验数据。

展开英文摘要原文

In recent decades, chimeric antigen receptor T (CAR-T) cell therapy has achieved dramatic success in patients with hematological malignancies.

However, CAR-T cell therapy failed to effectively treat solid tumors as a monotherapy. By summarizing the challenges of CAR-T cell monotherapy for solid tumors and analyzing the underlying mechanisms of combinatorial strategies to counteract these hurdles, we found that complementary therapeutics are needed to improve the scant and transient responses of CAR-T cell monotherapy in solid tumors.

Further data, especially data from multicenter clinical trials regarding efficacy, toxicity, and predictive biomarkers are required before the CAR-T combination therapy can be translated into clinical settings.

论文信息

作者
Yin L、Wan Z、Sun P、Shuai P、Liu Y
第一作者单位
Department of Health Management & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.China
通讯作者单位
Department of Health Management & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China. Electronic address: 18981838972@163.com.China
文献类型
综述 · 非美国政府资助研究
期刊
Biochimica et biophysica acta. Reviews on cancer2023 Jul
原文标识
PubMed 37286147 · DOI 10.1016/j.bbcan.2023.188930